COVID-19 Booster Vaccination
Hipra Scientific S.L. focuses on SARS-CoV-2 vaccination strategies in adults and adolescents, with research centred on heterologous booster use and adapted recombinant protein vaccine candidates for COVID-19.
- Booster immunisation in previously vaccinated populations
- Safety and tolerability evaluation
- Immunogenicity against emerging variants
The sponsor’s clinical work includes adults with prior mRNA vaccine exposure and adolescents receiving booster protection after primary vaccination.
SARS-CoV-2 Variant Response
Research activity also addresses immune responses to Omicron lineages, including variant-adapted vaccine approaches aimed at maintaining protection against circulating SARS-CoV-2 strains.
- Omicron XBB.1.16 immune response
- Omicron BA.1 neutralisation
- LP.8.1 variant coverage
These studies examine pseudovirus neutralisation outcomes and variant-specific antibody responses in vaccinated populations.
Adolescent and Young Adult Vaccination
The sponsor investigates COVID-19 booster vaccination in younger age groups, including adolescents and young adults, with emphasis on extending protection after initial Comirnaty vaccination.
- Adolescent booster immunisation
- Post-vaccination immune response
- Age-group comparison
Clinical interest extends to comparing immune responses across different adolescent and young adult cohorts.
Influenza and COVID-19 Co-administration
Hipra Scientific S.L. also studies the combined use of COVID-19 vaccination with seasonal influenza immunisation in older adults, reflecting interest in respiratory disease prevention across overlapping vaccination programmes.
- Coadministration with inactivated influenza vaccine
- Older adult vaccination
- Combined respiratory protection
This area links SARS-CoV-2 prevention with influenza vaccination in adults over 65 years of age.
